Actuate Therapeutics Inc. (NASDAQ: ACTU) announced plans to initiate a Phase 1/2 clinical program evaluating an oral tablet formulation of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE